<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Organoacid√§mien - Teil 1</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary-color: #8b5cf6;
            --secondary-color: #f59e0b;
            --accent-color: #ec4899;
            --success-color: #10b981;
            --warning-color: #f59e0b;
            --danger-color: #ef4444;
            --info-color: #3b82f6;
            --text-primary: #1f2937;
            --text-secondary: #4b5563;
            --text-muted: #6b7280;
            --bg-white: #ffffff;
            --bg-light: #f9fafb;
            --bg-lighter: #f3f4f6;
            --border-radius: 16px;
            --border-radius-lg: 24px;
            --spacing-xs: 8px;
            --spacing-sm: 16px;
            --spacing-md: 24px;
            --spacing-lg: 32px;
            --spacing-xl: 48px;
            --shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            --shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
            --shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }
        
        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%);
            min-height: 100vh;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: var(--spacing-md);
        }
        
        /* Header */
        .header {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-md);
            border: 1px solid #e5e7eb;
        }
        
        .header h1 {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
            background-size: 200% 200%;
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: clamp(2rem, 5vw, 3.5rem);
            font-weight: 700;
            margin-bottom: var(--spacing-sm);
            animation: gradientShift 4s ease-in-out infinite;
        }
        
        @keyframes gradientShift {
            0%, 100% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
        }
        
        .header p {
            color: var(--text-secondary);
            font-size: 1.3rem;
            font-weight: 400;
        }
        
        /* Progress bar */
        .progress-container {
            background: var(--bg-lighter);
            border-radius: 50px;
            height: 10px;
            margin-top: var(--spacing-md);
            overflow: hidden;
        }
        
        .progress-fill {
            background: linear-gradient(90deg, var(--primary-color), var(--secondary-color));
            height: 100%;
            border-radius: 50px;
            transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
            position: relative;
            overflow: hidden;
        }
        
        .progress-fill::after {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
            animation: progressShimmer 2s infinite;
        }
        
        @keyframes progressShimmer {
            0% { transform: translateX(-100%); }
            100% { transform: translateX(100%); }
        }
        
        /* Navigation */
        .navigation {
            background: var(--bg-white);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            display: flex;
            flex-wrap: wrap;
            gap: var(--spacing-sm);
            justify-content: center;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e5e7eb;
        }
        
        .nav-btn {
            background: var(--bg-light);
            border: 2px solid #e5e7eb;
            color: var(--text-primary);
            padding: 16px 24px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 14px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .nav-btn:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
            border-color: var(--primary-color);
        }
        
        .nav-btn.active {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }
        
        /* Content sections */
        .content-section {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            box-shadow: var(--shadow-md);
            border: 1px solid #e5e7eb;
            display: none;
        }
        
        .content-section.active {
            display: block;
            animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
        }
        
        @keyframes slideInUp {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .section-title {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: var(--spacing-lg);
            position: relative;
            padding-bottom: var(--spacing-sm);
        }
        
        .section-title::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 4px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            border-radius: 2px;
            animation: expandWidth 0.8s ease-out 0.3s both;
        }
        
        @keyframes expandWidth {
            from { width: 0; }
            to { width: 60px; }
        }
        
        /* Subsections */
        .subsection {
            margin-bottom: var(--spacing-lg);
            padding: var(--spacing-lg);
            background: var(--bg-light);
            border-radius: var(--border-radius);
            border: 1px solid #e5e7eb;
            transition: all 0.3s ease;
        }
        
        .subsection:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
        }
        
        .subsection h3 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.5rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .subsection h3::before {
            content: '';
            width: 4px;
            height: 24px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            border-radius: 2px;
        }
        
        .subsection p {
            color: var(--text-secondary);
            margin-bottom: 1rem;
            line-height: 1.7;
        }
        
        .subsection ul {
            color: var(--text-secondary);
            padding-left: 1.5rem;
        }
        
        .subsection li {
            margin-bottom: 0.5rem;
        }
        
        /* Tables */
        .clinical-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: var(--spacing-md) 0;
            background: var(--bg-white);
            border-radius: var(--border-radius);
            overflow: hidden;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e5e7eb;
        }
        
        .clinical-table th {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: var(--spacing-md);
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .clinical-table td {
            padding: var(--spacing-md);
            border-bottom: 1px solid #f3f4f6;
            transition: all 0.3s ease;
            color: var(--text-primary);
        }
        
        .clinical-table tbody tr:hover {
            background: #f9fafb;
        }
        
        .clinical-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Pathway diagrams */
        .pathway-diagram {
            background: var(--bg-white);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .pathway-diagram h4 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            text-align: center;
        }
        
        .pathway-diagram h5 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-sm);
            font-weight: 600;
        }
        
        .pathway-diagram p {
            color: var(--text-secondary);
        }
        
        /* Enzyme boxes */
        .enzyme-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: 12px 20px;
            margin: 6px;
            border-radius: 12px;
            font-weight: 600;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .enzyme-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        .enzyme-box.defect {
            background: linear-gradient(135deg, var(--danger-color), #dc2626);
            animation: pulseGlow 2s infinite;
        }
        
        @keyframes pulseGlow {
            0%, 100% {
                transform: scale(1);
                box-shadow: var(--shadow-sm);
            }
            50% {
                transform: scale(1.02);
                box-shadow: var(--shadow-md);
            }
        }
        
        .arrow {
            display: inline-block;
            margin: 0 var(--spacing-sm);
            font-size: 1.8rem;
            color: var(--primary-color);
            transition: all 0.3s ease;
        }
        
        .arrow:hover {
            transform: scale(1.2);
            color: var(--accent-color);
        }
        
        /* Highlight boxes */
        .highlight-box {
            background: linear-gradient(135deg, #fef3c7, #fde68a);
            border: 2px solid var(--warning-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            position: relative;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box::before {
            content: '‚ö†Ô∏è';
            position: absolute;
            top: -12px;
            left: 24px;
            background: linear-gradient(135deg, var(--warning-color), #fbbf24);
            padding: 8px 12px;
            border-radius: 50%;
            font-size: 1.2rem;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box h4 {
            color: #92400e;
            margin-bottom: var(--spacing-sm);
            margin-top: var(--spacing-sm);
            font-weight: 600;
        }
        
        .highlight-box p, .highlight-box ul, .highlight-box li {
            color: #92400e;
        }
        
        /* Case study boxes */
        .case-study {
            background: linear-gradient(135deg, #ecfdf5, #d1fae5);
            border: 2px solid var(--success-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .case-study h4 {
            color: #065f46;
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .case-study p, .case-study ul, .case-study li {
            color: #065f46;
        }
        
        /* Metabolite boxes */
        .metabolite-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--accent-color), #f97316);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .metabolite-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        /* Buttons */
        .next-step {
            text-align: center;
            margin-top: var(--spacing-xl);
        }
        
        .next-btn {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border: none;
            padding: 18px 36px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 16px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            box-shadow: var(--shadow-md);
            text-transform: uppercase;
            letter-spacing: 1px;
        }
        
        .next-btn:hover {
            transform: translateY(-4px) scale(1.05);
            box-shadow: var(--shadow-lg);
        }
        
        .part-info {
            background: linear-gradient(135deg, #ede9fe, #ddd6fe);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-sm);
        }
        
        .part-info h3 {
            color: var(--primary-color);
            margin-bottom: var(--spacing-sm);
        }
        
        .part-info p {
            color: var(--text-secondary);
        }
        
        /* Responsive design */
        @media (max-width: 768px) {
            .container {
                padding: var(--spacing-sm);
            }
            
            .header h1 {
                font-size: 2.5rem;
            }
            
            .header p {
                font-size: 1.1rem;
            }
            
            .navigation {
                flex-direction: column;
            }
            
            .nav-btn {
                width: 100%;
                text-align: center;
            }
            
            .content-section {
                padding: var(--spacing-md);
            }
            
            .section-title {
                font-size: 2rem;
            }
            
            .subsection {
                padding: var(--spacing-md);
            }
        }
        
        @media (max-width: 480px) {
            .header {
                padding: var(--spacing-md);
            }
            
            .header h1 {
                font-size: 2rem;
            }
            
            .section-title {
                font-size: 1.8rem;
            }
        }
        
        /* Animation stagger */
        .subsection {
            animation: fadeInStagger 0.6s ease-out both;
        }
        
        @keyframes fadeInStagger {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .subsection:nth-child(1) { animation-delay: 0.1s; }
        .subsection:nth-child(2) { animation-delay: 0.2s; }
        .subsection:nth-child(3) { animation-delay: 0.3s; }
        .subsection:nth-child(4) { animation-delay: 0.4s; }
        .subsection:nth-child(5) { animation-delay: 0.5s; }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>üß¨ Organoacid√§mien</h1>
            <p>Teil 1: Grundlagen & Biochemie</p>
            <div class="progress-container">
                <div class="progress-fill" id="progressBar" style="width: 0%"></div>
            </div>
        </div>

        <div class="part-info">
            <h3>üìö Lerneinheit Teil 1</h3>
            <p>Dieser erste Teil behandelt die Grundlagen, Biochemie, Pathophysiologie und klinischen Manifestationen der f√ºnf wichtigsten Organoacid√§mien.</p>
        </div>

        <div class="navigation">
            <button class="nav-btn active" onclick="showSection('grundlagen')">1. Grundlagen</button>
            <button class="nav-btn" onclick="showSection('biochemie')">2. Biochemie</button>
            <button class="nav-btn" onclick="showSection('pathophysiologie')">3. Pathophysiologie</button>
            <button class="nav-btn" onclick="showSection('klinik')">4. Klinische Manifestationen</button>
        </div>

        <!-- Grundlagen -->
        <div class="content-section active" id="grundlagen">
            <h2 class="section-title">üéØ Grundlagen der Organoacid√§mien</h2>
            
            <div class="subsection">
                <h3>Definition und Klassifikation</h3>
                <p>Organoacid√§mien sind angeborene Stoffwechseldefekte organischer S√§uren, die durch Enzymdefekte in den Abbauwegen verzweigtkettiger Aminos√§uren und anderen metabolischen Pathways entstehen.</p>
                
                <div class="highlight-box">
                    <h4>Die "Big Five" Organoacid√§mien</h4>
                    <ul>
                        <li><strong>Methylmalonacid√§mie (MMA)</strong> - H√§ufigste und schwerste Form</li>
                        <li><strong>Propionacid√§mie (PA)</strong> - Zweith√§ufigste, √§hnlich schwer wie MMA</li>
                        <li><strong>Isovalerianacid√§mie (IVA)</strong> - Erste beschriebene Organoacid√§mie</li>
                        <li><strong>Glutaracid√§mie Typ I (GA-I)</strong> - Bewegungsst√∂rungen im Vordergrund</li>
                        <li><strong>3-Methylcrotonyl-CoA-Carboxylase-Mangel (3-MCC)</strong> - Mildeste Form</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Epidemiologie und Genetik</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Erkrankung</th>
                            <th>Inzidenz</th>
                            <th>Vererbung</th>
                            <th>Hauptgene</th>
                            <th>Screening seit</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Methylmalonacid√§mie</strong></td>
                            <td>1:25.000 - 1:50.000</td>
                            <td>autosomal-rezessiv</td>
                            <td>MUT, MMAA, MMAB, MMADHC</td>
                            <td>2005 (Deutschland)</td>
                        </tr>
                        <tr>
                            <td><strong>Propionacid√§mie</strong></td>
                            <td>1:50.000 - 1:100.000</td>
                            <td>autosomal-rezessiv</td>
                            <td>PCCA, PCCB</td>
                            <td>2005 (Deutschland)</td>
                        </tr>
                        <tr>
                            <td><strong>Isovalerianacid√§mie</strong></td>
                            <td>1:100.000 - 1:250.000</td>
                            <td>autosomal-rezessiv</td>
                            <td>IVD</td>
                            <td>2005 (Deutschland)</td>
                        </tr>
                        <tr>
                            <td><strong>Glutaracid√§mie Typ I</strong></td>
                            <td>1:100.000 (1:300 in Amish)</td>
                            <td>autosomal-rezessiv</td>
                            <td>GCDH</td>
                            <td>2005 (Deutschland)</td>
                        </tr>
                        <tr>
                            <td><strong>3-MCC-Mangel</strong></td>
                            <td>1:50.000 (h√§ufigste im Screening)</td>
                            <td>autosomal-rezessiv</td>
                            <td>MCCC1, MCCC2</td>
                            <td>2005 (Deutschland)</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Gemeinsame pathophysiologische Prinzipien</h3>
                <div class="pathway-diagram">
                    <h4>Vier Hauptmechanismen der Pathogenese</h4>
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 12px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 15px;">üí£ Toxische Akkumulation</h5>
                            <p style="color: #dc2626;">Anstau organischer S√§uren</p>
                            <div class="arrow" style="color: #dc2626;">‚Üì</div>
                            <p style="color: #dc2626;">Azidose, Organsch√§digung</p>
                        </div>
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fff7ed, #fed7aa); border-radius: 12px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 15px;">‚ö° Energiedefizit</h5>
                            <p style="color: #ea580c;">Gest√∂rte Glukoneogenese</p>
                            <div class="arrow" style="color: #ea580c;">‚Üì</div>
                            <p style="color: #ea580c;">Hypoglyk√§mie</p>
                        </div>
                    </div>
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: 12px; border: 2px solid #3b82f6;">
                            <h5 style="color: #2563eb; margin-bottom: 15px;">üß† Neurotoxizit√§t</h5>
                            <p style="color: #2563eb;">Organische S√§uren passieren BHS</p>
                            <div class="arrow" style="color: #2563eb;">‚Üì</div>
                            <p style="color: #2563eb;">Direkte ZNS-Sch√§digung</p>
                        </div>
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #f0fdf4, #dcfce7); border-radius: 12px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 15px;">üîÑ Sekund√§re Effekte</h5>
                            <p style="color: #16a34a;">Hyperammon√§mie</p>
                            <div class="arrow" style="color: #16a34a;">‚Üì</div>
                            <p style="color: #16a34a;">Komplikationen</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Newborn Screening: Revolution√§re Fr√ºherkennung</h3>
                <div class="case-study">
                    <h4>üè• Screening-Erfolg in Deutschland seit 2005</h4>
                    <p><strong>Tandem-MS erm√∂glicht simultane Detektion:</strong></p>
                    <ul>
                        <li>C3 (Propionyl-CoA) f√ºr Propionacid√§mie und MMA</li>
                        <li>C5 (Isovaleryl-CoA) f√ºr Isovalerianacid√§mie</li>
                        <li>3-OH-Isovaleryl-CoA f√ºr 3-MCC-Mangel</li>
                        <li>Glutaryl-CoA f√ºr Glutaracid√§mie (zus√§tzlich)</li>
                    </ul>
                    
                    <p><strong>Screening-Impact:</strong></p>
                    <ul>
                        <li><strong>Pr√§symptomatische Diagnose:</strong> 85-90% aller F√§lle</li>
                        <li><strong>Mortalit√§tsreduktion:</strong> Von 40% auf <10% (schwere Formen)</li>
                        <li><strong>Neurologische Outcome:</strong> Drastische Verbesserung bei GA-I</li>
                        <li><strong>Falsch-positive Rate:</strong> <0,1% (sehr spezifisch)</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('biochemie')">Weiter zur Biochemie ‚Üí</button>
            </div>
        </div>

        <!-- Biochemie -->
        <div class="content-section" id="biochemie">
            <h2 class="section-title">‚öóÔ∏è Biochemische Pathways - Detailwissen</h2>
            
            <div class="subsection">
                <h3>1. Methylmalonacid√§mie: Propionyl-CoA-Pathway</h3>
                <div class="pathway-diagram">
                    <h4>Der Propionyl-CoA zu Succinyl-CoA Weg</h4>
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Propionyl-CoA</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Propionyl-CoA-Carboxylase</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Methylmalonyl-CoA</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 1: Carboxylierung (Biotin-abh√§ngig)</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Methylmalonyl-CoA</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Methylmalonyl-CoA-Racemase</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">(S)-Methylmalonyl-CoA</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 2: Stereoisomerie-Umwandlung</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">(S)-Methylmalonyl-CoA</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box defect">Methylmalonyl-CoA-Mutase</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Succinyl-CoA</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 3: Umlagerung (Cobalamin-abh√§ngig) ‚Üê DEFEKT</div>
                    </div>
                    
                    <p style="text-align: center; font-weight: bold; margin-top: 1rem;"><strong>Succinyl-CoA</strong> ‚Üí Eintritt in Citratzyklus (Energiegewinnung)</p>
                </div>

                <div class="highlight-box">
                    <h4>Cobalamin-Stoffwechsel: Der Schl√ºssel zu MMA</h4>
                    <p><strong>Zwei Cobalamin-abh√§ngige Enzyme:</strong></p>
                    <ul>
                        <li><strong>Methylmalonyl-CoA-Mutase:</strong> Ben√∂tigt Adenosylcobalamin (AdoCbl)</li>
                        <li><strong>Methionin-Synthase:</strong> Ben√∂tigt Methylcobalamin (MeCbl)</li>
                    </ul>
                    
                    <p><strong>MMA-Klassifikation nach Cobalamin-Responsivit√§t:</strong></p>
                    <ul>
                        <li><strong>mut0:</strong> Kompletter Mutase-Defekt, nicht B12-responsiv</li>
                        <li><strong>mut-:</strong> Partieller Mutase-Defekt, teilweise B12-responsiv</li>
                        <li><strong>cblA, cblB:</strong> AdoCbl-Synthesedefekte, B12-responsiv</li>
                        <li><strong>cblC, cblD:</strong> Kombinierte Defekte (MMA + Homocystinurie)</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>2. Propionacid√§mie: Biotinabh√§ngige Carboxylierung</h3>
                <div class="pathway-diagram">
                    <h4>Propionyl-CoA-Carboxylase (PCC) Reaktion</h4>
                    <div style="background: #f8fafc; padding: 15px; border-radius: 8px; margin: 15px 0; border: 1px solid #e2e8f0;">
                        <p><strong>Reaktion:</strong> Propionyl-CoA + CO‚ÇÇ + ATP ‚Üí Methylmalonyl-CoA + ADP + Pi</p>
                        <div style="font-family: monospace; font-size: 1.1em; margin: 10px 0; text-align: center;">
                            <span style="color: #dc2626;">CH‚ÇÉ-CH‚ÇÇ-CO-SCoA</span> + 
                            <span style="color: #2563eb;">CO‚ÇÇ</span> + 
                            <span style="color: #16a34a;">ATP</span>
                            <br>‚Üì PCC (Biotin)
                            <br><span style="color: #8b5cf6;">CH‚ÇÉ-CH(COOH)-CO-SCoA</span> + 
                            <span style="color: #f59e0b;">ADP + Pi</span>
                        </div>
                    </div>

                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div>
                            <h5 style="color: #dc2626; margin-bottom: 10px;">üî• Substratquellen f√ºr Propionyl-CoA</h5>
                            <div class="metabolite-box" style="margin: 5px 0; width: 100%; text-align: center;">Valin, Isoleucin (BCAA)</div>
                            <div class="metabolite-box" style="margin: 5px 0; width: 100%; text-align: center;">Threonin, Methionin</div>
                            <div class="metabolite-box" style="margin: 5px 0; width: 100%; text-align: center;">Odd-chain Fetts√§uren</div>
                            <div class="metabolite-box" style="margin: 5px 0; width: 100%; text-align: center;">Cholesterol Seitenkette</div>
                        </div>
                        <div>
                            <h5 style="color: #2563eb; margin-bottom: 10px;">‚ö° PCC-Struktur</h5>
                            <div class="enzyme-box" style="margin: 5px 0; width: 100%; text-align: center;">Œ±-Untereinheit (PCCA)</div>
                            <div class="enzyme-box" style="margin: 5px 0; width: 100%; text-align: center;">Œ≤-Untereinheit (PCCB)</div>
                            <div class="enzyme-box" style="margin: 5px 0; width: 100%; text-align: center;">Biotin-Cofaktor</div>
                            <div class="enzyme-box" style="margin: 5px 0; width: 100%; text-align: center;">Mg¬≤‚Å∫/Mn¬≤‚Å∫-abh√§ngig</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>3. Isovalerianacid√§mie: Leucin-Abbauweg</h3>
                <div class="pathway-diagram">
                    <h4>Leucin-Katabolismus - Der erste Schritt</h4>
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Leucin</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">BCAA-Transaminase</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Œ±-Ketoisocaproat</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 1: Transaminierung (reversibel)</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Œ±-Ketoisocaproat</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">BCKD-Komplex</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Isovaleryl-CoA</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 2: Oxidative Decarboxylierung (irreversibel)</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Isovaleryl-CoA</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box defect">Isovaleryl-CoA-DH</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">3-Methylcrotonyl-CoA</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 3: Dehydrierung (FAD-abh√§ngig) ‚Üê DEFEKT</div>
                    </div>
                </div>

                <div class="case-study">
                    <h4>üî¨ "Sweaty Feet Odor" - Charakteristisches Symptom</h4>
                    <p><strong>Biochemische Grundlage des Geruchs:</strong></p>
                    <ul>
                        <li><strong>Isovaleryl-CoA akkumuliert</strong> ‚Üí Hydrolyse zu Isovalerians√§ure</li>
                        <li><strong>Isovalerians√§ure = "Schwei√ü"-Geruch</strong> (erkennbar bei 1-2 Œºmol/l)</li>
                        <li><strong>Isovalerylglycin-Bildung</strong> als Detoxifikationsweg</li>
                        <li><strong>Diagnostischer Marker:</strong> Isovalerylglycin im Urin (GC-MS)</li>
                    </ul>
                    
                    <p><strong>Alternative Abbauwege:</strong></p>
                    <ul>
                        <li>Konjugation mit Glycin ‚Üí Isovalerylglycin (Hauptweg)</li>
                        <li>Konjugation mit Carnitin ‚Üí Isovalerylcarnitin</li>
                        <li>Hydroxylierung ‚Üí 3-Hydroxyisovalerians√§ure</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>4. Glutaracid√§mie Typ I: Lysin/Tryptophan-Degradation</h3>
                <div class="pathway-diagram">
                    <h4>Glutaryl-CoA-Dehydrogenase Reaktion</h4>
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div>
                            <h5 style="color: #8b5cf6; margin-bottom: 15px;">üìç Lysin-Pathway</h5>
                            <div style="display: flex; flex-direction: column; align-items: center; gap: 10px;">
                                <div class="metabolite-box">Lysin</div>
                                <div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
                                <div class="metabolite-box">Saccharopin</div>
                                <div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
                                <div class="metabolite-box">Œ±-Aminoadipat</div>
                                <div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
                                <div class="metabolite-box">Glutaryl-CoA</div>
                            </div>
                        </div>
                        <div>
                            <h5 style="color: #f59e0b; margin-bottom: 15px;">üîÑ Tryptophan-Pathway</h5>
                            <div style="display: flex; flex-direction: column; align-items: center; gap: 10px;">
                                <div class="metabolite-box">Tryptophan</div>
                                <div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
                                <div class="metabolite-box">Kynurenin</div>
                                <div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
                                <div class="metabolite-box">2-Aminoadipat</div>
                                <div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
                                <div class="metabolite-box">Glutaryl-CoA</div>
                            </div>
                        </div>
                    </div>
                    
                    <div style="text-align: center; margin: 20px 0; padding: 20px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 12px; border: 2px solid #ef4444;">
                        <div class="enzyme-box defect" style="font-size: 1.2em;">Glutaryl-CoA-Dehydrogenase (GCDH) ‚Üê DEFEKT</div>
                        <div class="arrow" style="margin: 15px 0; color: #dc2626;">‚Üì BLOCKADE</div>
                        <div style="color: #dc2626; font-weight: bold;">Glutaryl-CoA + 3-Hydroxyglutars√§ure akkumulieren</div>
                    </div>
                </div>

                <div class="highlight-box">
                    <h4>Striatal Vulnerability: Warum die Basalganglien?</h4>
                    <p><strong>Selektive Neurotoxizit√§t erkl√§rt sich durch:</strong></p>
                    <ul>
                        <li><strong>Hohe GCDH-Expression im Striatum</strong> physiologisch</li>
                        <li><strong>Glutars√§ure wirkt als NMDA-Agonist</strong> ‚Üí Excitotoxizit√§t</li>
                        <li><strong>Unreife Blut-Hirn-Schranke</strong> bei S√§uglingen durchl√§ssiger</li>
                        <li><strong>Energiedefizit</strong> besonders in metabolisch aktiven Neuronen</li>
                    </ul>
                    
                    <p><strong>Klinische Konsequenz:</strong></p>
                    <ul>
                        <li><strong>Akute Encephalopathic Crisis</strong> f√ºhrt zu irreversiblem Striatumschaden</li>
                        <li><strong>Pr√§vention durch Lysinarme Di√§t</strong> reduziert Substratanfall</li>
                        <li><strong>Fr√ºhe Diagnose entscheidend</strong> (Fenster bis ~2 Jahre)</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>5. 3-Methylcrotonyl-CoA-Carboxylase-Mangel: Leucin-Zweitzschritt</h3>
                <div class="pathway-diagram">
                    <h4>Leucin-Abbau nach Isovaleryl-CoA-DH</h4>
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">3-Methylcrotonyl-CoA</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box defect">3-Methylcrotonyl-CoA-Carboxylase</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">3-Methylglutaconyl-CoA</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 4 Leucin-Abbau: Carboxylierung (Biotin-abh√§ngig) ‚Üê DEFEKT</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">3-Methylglutaconyl-CoA</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">3-Methylglutaconyl-CoA-Hydratase</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">3-Hydroxy-3-Methylglutaryl-CoA</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 5: Hydratisierung (normal)</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">HMG-CoA</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">HMG-CoA-Lyase</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Acetoacetyl-CoA + Acetat</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 6: Spaltung ‚Üí Ketogene Endprodukte</div>
                    </div>
                </div>

                <div class="case-study">
                    <h4>üí° 3-MCC: Paradigma der "milden" Organoacid√§mie</h4>
                    <p><strong>Charakteristika:</strong></p>
                    <ul>
                        <li><strong>H√§ufigste Organoacid√§mie im Screening</strong> (1:50.000)</li>
                        <li><strong>Meist asymptomatisch</strong> oder sehr milde Symptome</li>
                        <li><strong>Biotin-responsiv</strong> in etwa 50% der F√§lle</li>
                        <li><strong>Alternative Abbauwege effektiv:</strong> 3-Hydroxyisovalerians√§ure</li>
                    </ul>
                    
                    <p><strong>Screening-Marker:</strong></p>
                    <ul>
                        <li><strong>3-Hydroxyisovaleryl-Carnitin (C5-OH)</strong> im Blut erh√∂ht</li>
                        <li><strong>3-Hydroxyisovalerians√§ure</strong> im Urin (GC-MS)</li>
                        <li><strong>3-Methylcrotonylglycin</strong> (weniger spezifisch)</li>
                    </ul>
                    
                    <p><strong>Management-Kontroverse:</strong></p>
                    <ul>
                        <li><strong>Behandlungsbed√ºrftigkeit umstritten</strong> bei asymptomatischen</li>
                        <li><strong>Pr√§ventive Biotin-Gabe</strong> oft empfohlen (harmlos)</li>
                        <li><strong>Stress-Situationen √ºberwachen</strong> (Infekte, Operationen)</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('pathophysiologie')">Weiter zur Pathophysiologie ‚Üí</button>
            </div>
        </div>

        <!-- Pathophysiologie -->
        <div class="content-section" id="pathophysiologie">
            <h2 class="section-title">üß† Pathophysiologie - Mechanismen der Sch√§digung</h2>
            
            <div class="subsection">
                <h3>Toxische Mechanismen organischer S√§uren</h3>
                <div class="pathway-diagram">
                    <h4>Zellul√§re Sch√§digungsmechanismen</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(280px, 1fr)); gap: 20px; margin: 20px 0;">
                        <div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 10px;">üî• Mitochondriale Toxizit√§t</h5>
                            <ul style="font-size: 0.9em; color: #dc2626;">
                                <li>CoA-Sequestration ‚Üí Energiemangel</li>
                                <li>Elektronentransportketten-Hemmung</li>
                                <li>Oxidativer Stress ‚Üë</li>
                                <li>Apoptose-Induktion</li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #fff7ed, #fed7aa); padding: 15px; border-radius: 8px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 10px;">‚öñÔ∏è Metabolische Azidose</h5>
                            <ul style="font-size: 0.9em; color: #ea580c;">
                                <li>Akkumulation organischer S√§uren</li>
                                <li>Lactat-Anstieg (sekund√§r)</li>
                                <li>Ketose-Hemmung</li>
                                <li>Elektrolytverschiebungen</li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 15px; border-radius: 8px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 10px;">üß¨ Epigenetische Effekte</h5>
                            <ul style="font-size: 0.9em; color: #16a34a;">
                                <li>Histon-Deacetylase-Hemmung</li>
                                <li>Genexpression ver√§ndert</li>
                                <li>Entwicklungsst√∂rungen</li>
                                <li>Langzeitfolgen</li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #eff6ff, #dbeafe); padding: 15px; border-radius: 8px; border: 2px solid #3b82f6;">
                            <h5 style="color: #2563eb; margin-bottom: 10px;">üß† Neurotransmitter-St√∂rung</h5>
                            <ul style="font-size: 0.9em; color: #2563eb;">
                                <li>GABA/Glutamat Imbalance</li>
                                <li>Dopamin-Synthese ‚Üì</li>
                                <li>Synaptic pruning gest√∂rt</li>
                                <li>Myelination verz√∂gert</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Hyperammon√§mie: Der gemeinsame Endpunkt</h3>
                <div class="highlight-box">
                    <h4>Mechanismen der Ammoniak-Akkumulation bei Organoacid√§mien</h4>
                    <p><strong>1. Direkte Harnstoffzyklus-Hemmung:</strong></p>
                    <ul>
                        <li><strong>N-Acetylglutamat-Synthase Inhibition</strong> durch Propionyl-CoA</li>
                        <li><strong>CPS1-Aktivit√§t ‚Üì</strong> (N-Acetylglutamat = allosterischer Aktivator)</li>
                        <li><strong>Argininosuccinat-Synthetase Hemmung</strong> durch organische S√§uren</li>
                    </ul>

                    <p><strong>2. Sekund√§re metabolische Effekte:</strong></p>
                    <ul>
                        <li><strong>ATP-Verbrauch ‚Üë</strong> durch Detoxifikation ‚Üí Energiemangel</li>
                        <li><strong>Aspartat-Mangel</strong> durch gest√∂rte Glukoneogenese</li>
                        <li><strong>Glutamin-Synthese kompensatorisch ‚Üë</strong> ‚Üí Hirn√∂dem</li>
                    </ul>

                    <p><strong>3. Hepatische Toxizit√§t:</strong></p>
                    <ul>
                        <li><strong>Hepatozyten-Sch√§digung</strong> durch organische S√§uren direkt</li>
                        <li><strong>Mikrozirkulationsst√∂rungen</strong></li>
                        <li><strong>Proteinsynthese ‚Üì</strong> (einschlie√ülich Harnstoffzyklus-Enzyme)</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Erkrankungsspezifische Pathomechanismen</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Erkrankung</th>
                            <th>Haupttoxin</th>
                            <th>Pathomechanismus</th>
                            <th>Zielorgan</th>
                            <th>Spezifische Folgen</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Methylmalonacid√§mie</strong></td>
                            <td>Methylmalons√§ure, Propions√§ure</td>
                            <td>Mitochondriale Dysfunktion, CoA-Sequestration</td>
                            <td>Niere, ZNS, Herz</td>
                            <td>Tubulopathie, Enzephalopathie, Kardiomyopathie</td>
                        </tr>
                        <tr>
                            <td><strong>Propionacid√§mie</strong></td>
                            <td>Propions√§ure, 3-OH-Propions√§ure</td>
                            <td>Mitochondriale Toxizit√§t, Pankreatitis</td>
                            <td>Pankreas, ZNS, Herz</td>
                            <td>Pankreatitis, Basalganglien-Infarkte</td>
                        </tr>
                        <tr>
                            <td><strong>Isovalerianacid√§mie</strong></td>
                            <td>Isovalerians√§ure</td>
                            <td>Milde mitochondriale St√∂rung</td>
                            <td>ZNS (gering)</td>
                            <td>Meist milde neurologische Symptome</td>
                        </tr>
                        <tr>
                            <td><strong>Glutaracid√§mie I</strong></td>
                            <td>Glutars√§ure, 3-OH-Glutars√§ure</td>
                            <td>NMDA-Rezeptor-Aktivierung, Excitotoxizit√§t</td>
                            <td>Striatum</td>
                            <td>Dystonie, choreoathet√∂se Bewegungen</td>
                        </tr>
                        <tr>
                            <td><strong>3-MCC-Mangel</strong></td>
                            <td>3-Methylcrotons√§ure</td>
                            <td>Sehr milde Toxizit√§t</td>
                            <td>Minimal</td>
                            <td>Meist asymptomatisch</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Entwicklungsspezifische Vulnerabilit√§t</h3>
                <div class="case-study">
                    <h4>üß† Das unreife Gehirn - Warum S√§uglinge besonders betroffen sind</h4>
                    <p><strong>Anatomische Faktoren:</strong></p>
                    <ul>
                        <li><strong>Unreife Blut-Hirn-Schranke</strong> ‚Üí erh√∂hte Permeabilit√§t f√ºr Toxine</li>
                        <li><strong>Hohe Zellteilungsrate</strong> ‚Üí besonders vulnerabel f√ºr metabolische St√∂rungen</li>
                        <li><strong>Myelinisierung unvollst√§ndig</strong> ‚Üí gest√∂rte Signal√ºbertragung</li>
                        <li><strong>Energiebedarf relativ hoch</strong> ‚Üí Energiedefizit besonders kritisch</li>
                    </ul>

                    <p><strong>Metabolische Faktoren:</strong></p>
                    <ul>
                        <li><strong>Enzyme-Reifung unvollst√§ndig</strong> ‚Üí schlechtere Detoxifikation</li>
                        <li><strong>Glykogenspeicher gering</strong> ‚Üí schnellere Hypoglyk√§mie</li>
                        <li><strong>Proteinumsatz hoch</strong> ‚Üí mehr toxische Metaboliten</li>
                        <li><strong>Kompensationsmechanismen unreif</strong></li>
                    </ul>

                    <p><strong>Klinische Konsequenzen:</strong></p>
                    <ul>
                        <li><strong>Kritische Phasen:</strong> 1. Lebenswoche, 6-24 Monate</li>
                        <li><strong>Irreversible Sch√§den</strong> oft schon bei erster Dekompensation</li>
                        <li><strong>Fr√ºhe Diagnose essentiell</strong> ‚Üí Newborn Screening revolution√§r</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Molekulare Pathologie: Von Enzymdefekt zu klinischem Ph√§notyp</h3>
                <div class="pathway-diagram">
                    <h4>Die Kaskade von der Mutation zum klinischen Bild</h4>
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: linear-gradient(135deg, #fefce8, #fef3c7); padding: 15px; border-radius: 12px; border: 2px solid #f59e0b; width: 100%; text-align: center;">
                            <h5 style="color: #92400e; margin-bottom: 10px;">üß¨ Genetische Ebene</h5>
                            <p style="color: #92400e;">Mutation ‚Üí reduzierte/fehlende Enzymaktivit√§t</p>
                        </div>
                        <div class="arrow" style="transform: rotate(90deg); color: #f59e0b;">‚Üì</div>
                        
                        <div style="background: linear-gradient(135deg, #ecfdf5, #d1fae5); padding: 15px; border-radius: 12px; border: 2px solid #22c55e; width: 100%; text-align: center;">
                            <h5 style="color: #065f46; margin-bottom: 10px;">‚öóÔ∏è Biochemische Ebene</h5>
                            <p style="color: #065f46;">Substrat-Akkumulation + Produkt-Mangel</p>
                        </div>
                        <div class="arrow" style="transform: rotate(90deg); color: #22c55e;">‚Üì</div>
                        
                        <div style="background: linear-gradient(135deg, #eff6ff, #dbeafe); padding: 15px; border-radius: 12px; border: 2px solid #3b82f6; width: 100%; text-align: center;">
                            <h5 style="color: #1e40af; margin-bottom: 10px;">üî¨ Zellul√§re Ebene</h5>
                            <p style="color: #1e40af;">Mitochondriale Dysfunktion + oxidativer Stress</p>
                        </div>
                        <div class="arrow" style="transform: rotate(90deg); color: #3b82f6;">‚Üì</div>
                        
                        <div style="background: linear-gradient(135deg, #fdf2f8, #fce7f3); padding: 15px; border-radius: 12px; border: 2px solid #ec4899; width: 100%; text-align: center;">
                            <h5 style="color: #be185d; margin-bottom: 10px;">üß† Organebene</h5>
                            <p style="color: #be185d;">Gewebssch√§digung (ZNS, Leber, Niere, Herz)</p>
                        </div>
                        <div class="arrow" style="transform: rotate(90deg); color: #ec4899;">‚Üì</div>
                        
                        <div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 15px; border-radius: 12px; border: 2px solid #ef4444; width: 100%; text-align: center;">
                            <h5 style="color: #dc2626; margin-bottom: 10px;">üè• Klinische Ebene</h5>
                            <p style="color: #dc2626;">Symptome: Azidose, Hypoglyk√§mie, Hyperammon√§mie, neurologische Defizite</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('klinik')">Weiter zu den klinischen Manifestationen ‚Üí</button>
            </div>
        </div>

        <!-- Klinische Manifestationen -->
        <div class="content-section" id="klinik">
            <h2 class="section-title">üè• Klinische Manifestationen</h2>
            
            <div class="subsection">
                <h3>Altersabh√§ngige Pr√§sentationsmuster</h3>
                <div class="pathway-diagram">
                    <h4>Drei Hauptmanifestationsformen</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(300px, 1fr)); gap: 20px; margin: 20px 0;">
                        <div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 20px; border-radius: 12px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 15px;">üë∂ Neonatale Form (0-28 Tage)</h5>
                            <ul style="font-size: 0.9em; color: #dc2626;">
                                <li><strong>Schwere metabolische Azidose</strong></li>
                                <li><strong>Hyperammon√§mie >300 Œºmol/l</strong></li>
                                <li><strong>Bewusstseinstr√ºbung bis Koma</strong></li>
                                <li><strong>Apnoe-Episoden</strong></li>
                                <li><strong>Trinkschw√§che</strong></li>
                                <li><strong>Mortalit√§t: 30-50% unbehandelt</strong></li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #fff7ed, #fed7aa); padding: 20px; border-radius: 12px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 15px;">üçº Infantile Form (1-12 Monate)</h5>
                            <ul style="font-size: 0.9em; color: #ea580c;">
                                <li><strong>Gedeihst√∂rung, FTT</strong></li>
                                <li><strong>Entwicklungsverz√∂gerung</strong></li>
                                <li><strong>Rezidivierende Krisen</strong></li>
                                <li><strong>Hepatomegalie</strong></li>
                                <li><strong>Anfallsleiden m√∂glich</strong></li>
                                <li><strong>Prognose variabel</strong></li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 20px; border-radius: 12px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 15px;">üßí Sp√§te/Partielle Form (>1 Jahr)</h5>
                            <ul style="font-size: 0.9em; color: #16a34a;">
                                <li><strong>Milde Entwicklungsverz√∂gerung</strong></li>
                                <li><strong>Stress-induzierte Krisen</strong></li>
                                <li><strong>Chronische Probleme</strong></li>
                                <li><strong>Protein-Intoleranz</strong></li>
                                <li><strong>Normale Intelligenz m√∂glich</strong></li>
                                <li><strong>Beste Prognose</strong></li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Erkrankungsspezifische klinische Profile</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Organoacid√§mie</th>
                            <th>Typisches Erstmanifestationsalter</th>
                            <th>Charakteristische Symptome</th>
                            <th>Besonderheiten</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Methylmalonacid√§mie</strong></td>
                            <td>1. Lebenswoche bis 6 Monate</td>
                            <td>Schwere Azidose, Hyperammon√§mie, Nierenprobleme</td>
                            <td>B12-Responsivit√§t bei cbl-Formen</td>
                        </tr>
                        <tr>
                            <td><strong>Propionacid√§mie</strong></td>
                            <td>1. Lebenswoche bis 3 Monate</td>
                            <td>Schwere Azidose, Pankreatitis, Kardiomyopathie</td>
                            <td>Oddor (s√º√ülich), Basalganglien-Infarkte</td>
                        </tr>
                        <tr>
                            <td><strong>Isovalerianacid√§mie</strong></td>
                            <td>1. Lebenswoche oder 6-24 Monate</td>
                            <td>"Sweaty feet" Geruch, milde Azidose</td>
                            <td>Charakteristischer Geruch diagnostisch</td>
                        </tr>
                        <tr>
                            <td><strong>Glutaracid√§mie I</strong></td>
                            <td>6-18 Monate (encephalopathic crisis)</td>
                            <td>Akute Dystonie, Makrozephalie</td>
                            <td>Striatal-Sch√§den irreversibel</td>
                        </tr>
                        <tr>
                            <td><strong>3-MCC-Mangel</strong></td>
                            <td>Oft asymptomatisch</td>
                            <td>Milde Entwicklungsverz√∂gerung (wenn √ºberhaupt)</td>
                            <td>H√§ufigste im Screening, fragliche Pathogenit√§t</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Acute Dekompensation: Das klinische Notfallbild</h3>
                <div class="highlight-box">
                    <h4>Klassische Trias der akuten Krise</h4>
                    <p><strong>1. Metabolische Azidose mit erh√∂hter Anionenl√ºcke:</strong></p>
                    <ul>
                        <li><strong>pH <7,20, BE <-15 mmol/l</strong></li>
                        <li><strong>Anionenl√ºcke >20 mmol/l</strong> (organische S√§uren)</li>
                        <li><strong>Kompensatorische Hyperventilation</strong></li>
                        <li><strong>Kussmaul-Atmung bei schweren F√§llen</strong></li>
                    </ul>

                    <p><strong>2. Hyperammon√§mie:</strong></p>
                    <ul>
                        <li><strong>Moderant: 150-300 Œºmol/l</strong> (sekund√§r)</li>
                        <li><strong>Schwer: >300 Œºmol/l</strong> (Prognose‚Üì)</li>
                        <li><strong>Neurologische Symptome ab 100-150 Œºmol/l</strong></li>
                        <li><strong>Hirn√∂dem-Risiko ab 300 Œºmol/l</strong></li>
                    </ul>

                    <p><strong>3. Bewusstseinsst√∂rung progredient:</strong></p>
                    <ul>
                        <li><strong>Lethargie ‚Üí Somnolenz ‚Üí Sopor ‚Üí Koma</strong></li>
                        <li><strong>Krampfanf√§lle (20-30% der Krisen)</strong></li>
                        <li><strong>Fokale neurologische Ausf√§lle</strong> (besonders PA)</li>
                        <li><strong>Ateminsuffizienz als Endstadium</strong></li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Systemspezifische Manifestationen</h3>
                <div class="case-study">
                    <h4>ü´Ä Kardiale Beteiligung</h4>
                    <p><strong>H√§ufigkeit und Pattern:</strong></p>
                    <ul>
                        <li><strong>Propionacid√§mie:</strong> 10-15% entwickeln Kardiomyopathie</li>
                        <li><strong>Methylmalonacid√§mie:</strong> 5-10%, meist bei mut0-Form</li>
                        <li><strong>Typ:</strong> Dilatative > hypertrophe Kardiomyopathie</li>
                        <li><strong>Reversibilit√§t:</strong> Oft irreversibel, Tx-Indikation</li>
                    </ul>

                    <p><strong>Pathophysiologie:</strong></p>
                    <ul>
                        <li><strong>Direkte Toxizit√§t</strong> organischer S√§uren auf Myozyten</li>
                        <li><strong>Mitochondriale Dysfunktion</strong> ‚Üí Energiemangel</li>
                        <li><strong>Oxidativer Stress</strong> ‚Üí Fibrose</li>
                        <li><strong>Sekund√§re Elektrolytverschiebungen</strong></li>
                    </ul>
                </div>

                <div class="case-study">
                    <h4>üß† Neurologische Sp√§tfolgen</h4>
                    <p><strong>Bewegungsst√∂rungen (besonders GA-I und PA):</strong></p>
                    <ul>
                        <li><strong>Dystonie:</strong> H√§ufigste chronische Manifestation</li>
                        <li><strong>Choreoathetose:</strong> Bei Basalganglien-Sch√§den</li>
                        <li><strong>Spastik:</strong> Bei diffuser Hirnsch√§digung</li>
                        <li><strong>Ataxie:</strong> Seltener, bei Kleinhirn-Beteiligung</li>
                    </ul>

                    <p><strong>Kognitive Entwicklung:</strong></p>
                    <ul>
                        <li><strong>IQ-Bereich:</strong> 50-120 (sehr variabel)</li>
                        <li><strong>Faktoren:</strong> Anzahl der Krisen, Hyperammon√§mie-Schwere</li>
                        <li><strong>Lernst√∂rungen:</strong> H√§ufig auch bei milden Verl√§ufen</li>
                        <li><strong>Aufmerksamkeitsdefizite:</strong> ADHS-√§hnliche Symptome</li>
                    </ul>
                </div>

                <div class="case-study">
                    <h4>ü©∏ H√§matologische Auff√§lligkeiten</h4>
                    <p><strong>Neutropenie (h√§ufig bei PA und MMA):</strong></p>
                    <ul>
                        <li><strong>Inzidenz:</strong> 30-50% der Patienten</li>
                        <li><strong>Mechanismus:</strong> Knochenmark-Toxizit√§t durch organische S√§uren</li>
                        <li><strong>Klinik:</strong> Erh√∂hte Infektanf√§lligkeit</li>
                        <li><strong>Management:</strong> G-CSF bei schwerer Neutropenie</li>
                    </ul>

                    <p><strong>Megaloblast√§re An√§mie (MMA mit B12-Mangel):</strong></p>
                    <ul>
                        <li><strong>Bei cblC, cblD:</strong> Kombinierte MMA + Homocystinurie</li>
                        <li><strong>Mechanismus:</strong> Gest√∂rte B12-Utilisation</li>
                        <li><strong>Therapie:</strong> Hydroxocobalamin hochdosiert</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Trigger-Faktoren f√ºr akute Dekompensation</h3>
                <div class="pathway-diagram">
                    <h4>Die h√§ufigsten Ausl√∂ser - Pr√§ventionsans√§tze</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin: 20px 0;">
                        <div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 10px;">ü¶† Infektionen (60%)</h5>
                            <ul style="font-size: 0.9em; color: #dc2626;">
                                <li>Gastroenteritis mit Erbrechen</li>
                                <li>Fieberhafte Infekte</li>
                                <li>Reduktion der Proteinzufuhr</li>
                                <li><strong>Pr√§vention:</strong> Sick-day management</li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #fff7ed, #fed7aa); padding: 15px; border-radius: 8px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 10px;">üçΩÔ∏è Di√§tfehler (20%)</h5>
                            <ul style="font-size: 0.9em; color: #ea580c;">
                                <li>Protein-Exzess</li>
                                <li>Fasten >12h</li>
                                <li>Non-Compliance</li>
                                <li><strong>Pr√§vention:</strong> Di√§tschulung</li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 15px; border-radius: 8px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 10px;">‚öïÔ∏è Medizinische Eingriffe (10%)</h5>
                            <ul style="font-size: 0.9em; color: #16a34a;">
                                <li>Narkosen</li>
                                <li>Operationen</li>
                                <li>Kontrastmittel-Gabe</li>
                                <li><strong>Pr√§vention:</strong> Pr√§medikation</li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #eff6ff, #dbeafe); padding: 15px; border-radius: 8px; border: 2px solid #3b82f6;">
                            <h5 style="color: #2563eb; margin-bottom: 10px;">üéÇ Wachstumssch√ºbe (5%)</h5>
                            <ul style="font-size: 0.9em; color: #2563eb;">
                                <li>Erh√∂hter Protein-Turnover</li>
                                <li>Pubert√§t besonders kritisch</li>
                                <li>Schwangerschaft (bei Frauen)</li>
                                <li><strong>Pr√§vention:</strong> Anpassung der Therapie</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="next-step">
                <div style="text-align: center; margin-top: 2rem; padding: 2rem; background: linear-gradient(135deg, #ede9fe, #ddd6fe); border-radius: var(--border-radius); border: 2px solid var(--primary-color);">
                    <h3 style="color: var(--primary-color); margin-bottom: 1rem;">üéâ Teil 1 abgeschlossen!</h3>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;">Sie haben die Grundlagen, Biochemie, Pathophysiologie und klinischen Manifestationen der Organoacid√§mien erfolgreich durchgearbeitet.</p>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;"><strong>Als n√§chstes:</strong> Teil 2 mit Diagnostik, Therapie und Notfallmanagement</p>
                    <button class="next-btn">Weiter zu Teil 2 ‚Üí</button>
                </div>
            </div>
        </div>
    </div>

    <script>
        let currentSection = 0;
        const sections = ['grundlagen', 'biochemie', 'pathophysiologie', 'klinik'];

        function showSection(sectionId) {
            // Hide all sections
            const allSections = document.querySelectorAll('.content-section');
            allSections.forEach(section => section.classList.remove('active'));

            // Remove active class from all nav buttons
            const allButtons = document.querySelectorAll('.nav-btn');
            allButtons.forEach(btn => btn.classList.remove('active'));

            // Show selected section
            document.getElementById(sectionId).classList.add('active');

            // Highlight active nav button
            event.target.classList.add('active');

            // Update progress bar
            currentSection = sections.indexOf(sectionId);
            const progress = ((currentSection + 1) / sections.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';

            // Scroll to top
            window.scrollTo(0, 0);
        }

        // Initialize progress bar
        document.getElementById('progressBar').style.width = '25%';
    </script>
</body>
</html>